Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial

Emilio Gil, Fernando Garcia-Alonso, Anca Boldeanu, Thaïs Baleeiro Teixeira, Loxapine Inhaled Home Use study investigator’s team, Emilio Gil, Fernando Garcia-Alonso, Anca Boldeanu, Thaïs Baleeiro Teixeira, Loxapine Inhaled Home Use study investigator’s team

Abstract

Introduction: There is a need for fast-acting, non-injection antiagitation treatments that are well tolerated and can be used outside of healthcare facilities. In phase II/III trials, an inhaled formulation of loxapine (ADASUVE®), a well-established, first-generation antipsychotic agent, provided rapid control of mild to moderate agitation in the hospital setting. The present study was designed to investigate the safety and efficacy of inhaled loxapine when self-administered outside the hospital setting.

Methods and analysis: This phase IV, multicentre, single-arm, open-label clinical trial is being conducted in five countries in Europe: Spain, Germany, Norway, Romania and Austria. The aim is to include approximately 500 patients with schizophrenia or bipolar disorder who previously received and responded well to inhaled loxapine in the hospital setting. Eligible patients will be followed up for 6 months from baseline. They will be given a 10 mg dose of inhaled loxapine to self-administer outside the hospital setting to treat an agitation episode, should one occur. Patients will also be given a short-acting beta-agonist bronchodilator for treatment of possible severe respiratory side effects. The primary endpoint is incidence of serious adverse events (AEs) and respiratory AEs of special interest related to use of inhaled loxapine outside the hospital setting. Secondary endpoints include incidence of other AEs, Clinical Global Impression-Improvement scores up to 2 hours after self-administration of inhaled loxapine, time to improvement of agitation, patient satisfaction with treatment, treatment outcomes according to agitation severity and concordance between the patient (or a family member/caregiver) and the physician in scoring of agitation severity and the decision to self-administer inhaled loxapine.

Ethics and dissemination: The protocol received ethics committee approval in the participating countries between January and August 2016. The results of this study will be disseminated through one or more scientific papers.

Trial registration number: EudraCT2015-003331-36; NCT02525991; Pre-results.

Keywords: agitation; bipolar disorder; inhaled loxapine; safety; schizophrenia; self-administration.

Conflict of interest statement

Competing interests: All authors are employees of Ferrer Internacional S.A.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Overall design of the study.

References

    1. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001;9:89–104. 10.1080/10673220127892
    1. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry 2003;64:3–9.
    1. Battaglia J. The treatment of acute agitation in schizophrenia. CNS Spectr 2007;12:1–16. 10.1017/S1092852900026146
    1. San L, Marksteiner J, Zwanzger P, et al. . State of acute agitation at psychiatric emergencies in europe: the stage study. Clin Pract Epidemiol Ment Health 2016;12:75–86. 10.2174/1745017901612010075
    1. Pajonk FG, Schmitt P, Biedler A, et al. . Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings. Gen Hosp Psychiatry 2008;30:360–6. 10.1016/j.genhosppsych.2008.03.005
    1. Garriga M, Pacchiarotti I, Kasper S, et al. . Assessment and management of agitation in psychiatry: Expert consensus. World J Biol Psychiatry 2016;17:86–128. 10.3109/15622975.2015.1132007
    1. Serrano-Blanco A, Rubio-Valera M, Aznar-Lou I, et al. . In-patient costs of agitation and containment in a mental health catchment area. BMC Psychiatry 2017;17:212 10.1186/s12888-017-1373-4
    1. National Institute of Mental Health (NIMH). Statistics: Schizophrenia. .
    1. Health & Consumer Protection Directorate-General. The State of Mental Health in the European Union, 2004. .
    1. Wittchen HU, Jacobi F, Rehm J, et al. . The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655–79. 10.1016/j.euroneuro.2011.07.018
    1. World Health Organization. Mental health: Schizophrenia. .
    1. World Health Organization. The global burden of disease. 2004. .
    1. Merikangas KR, Jin R, He JP, J-p H, et al. . Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241–51. 10.1001/archgenpsychiatry.2011.12
    1. Pini S, de Queiroz V, Pagnin D, et al. . Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol 2005;15:425–34. 10.1016/j.euroneuro.2005.04.011
    1. Allen MH, Currier GW, Hughes DH, et al. . The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001:1–88.
    1. Breier A, Meehan K, Birkett M, et al. . A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441–8. 10.1001/archpsyc.59.5.441
    1. Tran-Johnson TK, Sack DA, Marcus RN, et al. . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:111–9.
    1. Heel RC, Brogden RN, Speight TM, et al. . Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978;15:198–217.
    1. Chakrabarti A, Bagnall A, Chue P, et al. . Loxapine for schizophrenia. Cochrane Database Syst Rev 2007;4:CD001943.
    1. Bourdinaud V, Pochard F. [Survey of management methods for patients in a state of agitation at admission and emergency departments in France]. Encephale 2003;29:89–98.
    1. ADASUVE®. Summary of product characteristics. .
    1. Allen MH, Feifel D, Lesem MD, et al. . Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:1313–21. 10.4088/JCP.10m06011yel
    1. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. . Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011;198:51–8. 10.1192/bjp.bp.110.081513
    1. Kwentus J, Riesenberg RA, Marandi M, et al. . Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 2012;14:31–40. 10.1111/j.1399-5618.2011.00975.x
    1. Wong JG, Clare CH, Holland AJ, et al. . The capacity of people with a ’mental disability' to make a health care decision. Psychol Med 2000;30:295–306. 10.1017/S0033291700001768
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, USA: U.S. Department of Health, Education, and Welfare, 1976.
    1. Busner J, Targum SD. The clinical global impressions scale. Psychiatry 2007;4:28–37.
    1. ADASUVE®. Highlights of prescribing information. .
    1. Cohen J. A Coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46. 10.1177/001316446002000104

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner